# Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
**SUMMARY:**
The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. This meeting was announced in the *Federal Register* of March 17, 2016. The amendment is being made to reflect a change in the *Date and Time* portion of the document. The *Date* of the meeting is changed to May 24, 2016. There are no other changes.
**FOR FURTHER INFORMATION CONTACT:**
LaToya Bonner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, *[email protected],* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.
**SUPPLEMENTARY INFORMATION:**
In the *Federal Register* of March 17, 2016 (81 FR 14448), FDA announced that a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would be held on May 25, 2016. On page 14449, in the first column, the *Date and Time* portion of the document is changed to read as follows:
*Date and Time:* The meeting will be held on May 24, 2016, from 8 a.m. to 5 p.m.
This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated:
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.